Abstract
The endocannabinoid system (ECS) is composed of cannabinoid receptors, their endogenous ligands, and the enzymes involved in endocannabinoid turnover. Modulating the activity of the ECS may influence a variety of physiological and pathophysiological processes. A growing body of evidence indicates that activation of cannabinoid receptors by endogenous, plant-derived, or synthetic cannabinoids may exert beneficial effects on gastrointestinal inflammation and visceral pain. The present ex vivo study aimed to investigate immunohistochemically the distribution of cannabinoid receptors CB1, CB2, G protein-coupled receptor 55 (GPR55), and peroxisome proliferation activation receptor alpha (PPARα) in the canine gastrointestinal tract. CB1 receptor immunoreactivity was observed in the lamina propria and epithelial cells. CB2 receptor immunoreactivity was expressed by lamina propria mast cells and immunocytes, blood vessels, and smooth muscle cells. Faint CB2 receptor immunoreactivity was also observed in neurons and glial cells of the submucosal plexus. GPR55 receptor immunoreactivity was expressed by lamina propria macrophages and smooth muscle cells. PPARα receptor immunoreactivity was expressed by blood vessels, smooth muscle cells, and glial cells of the myenteric plexus. Cannabinoid receptors showed a wide distribution in the gastrointestinal tract of the dog. Since cannabinoid receptors have a protective role in inflammatory bowel disease, the present research provides an anatomical basis supporting the therapeutic use of cannabinoid receptor agonists in relieving motility disorders and visceral hypersensitivity in canine acute or chronic enteropathies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aloe L, Leon A, Levi-Montalcini R (1993) A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions 39(Spec No):C145–C147
Ambrosino P, Soldovieri MV, Russo C et al (2013) Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide. Br J Pharmacol 168:1430–1434. https://doi.org/10.1111/bph.12029
Anday JK, Mercier RW (2005) Gene ancestry of the cannabinoid receptor family. Pharmacol Res 52:463–466
Argueta DA, DiPatrizio NV. (2017) Peripheral endocannabinoid signaling controls hyperphagia in western diet-induced obesity. Physiol Behav 171:32–39. https://doi.org/10.1016/j.physbeh.2016.12.044
Ashton JC, Friberg D, Darlington CL et al (2006) Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci Lett 396:113–116
Azuma YT, Nishiyama K, Matsuo Y et al (2010) PPARα contributes to colonic protection in mice with DSS-induced colitis. Int Immunopharmacol 10:1261–1267. https://doi.org/10.1016/j.intimp.2010.07.007
Bednarska O, Walter SA, Casado-Bedmar M et al (2017) Vasoactive intestinal polypeptide and mast cells regulate increased passage of colonic bacteria in patients with irritable bowel syndrome. Gastroenterology S0016-5085:948–960. https://doi.org/10.1053/j.gastro.2017.06.051
Benyó Z, Ruisanchez É, Leszl-Ishiguro M et al (2016) Endocannabinoids in cerebrovascular regulation. Am J Physiol Heart Circ Physiol 310:H785–H801. https://doi.org/10.1152/ajpheart.00571.2015
Bischoff SC (2016) Mast cells in gastrointestinal disorders. Eur J Pharmacol 778:139–145
Borrelli F, Romano B, Petrosino S et al (2015) Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent. Br J Pharmacol 172:142–158
Brown AJ, Ueno S, Suen K et al (2005) Molecular identification of GPR55 as a third G protein-coupled receptor responsive to cannabinoid ligands. In: Brian T (ed) Symposium on the cannabinoids, pp 24–27
Cabral GA, Raborn ES, Griffin L et al (2008) CB2 receptors in the brain: role in central immune function. Br J Pharmacol 153:240–251
Cabral GA, Rogers TJ, Lichtman AH (2015) Turning over a new leaf: cannabinoid and endocannabinoid modulation of immune function. J Neuroimmune Pharmacol 10:193–203. https://doi.org/10.1007/s11481-015-9615-z
Campora L, Miragliotta V, Ricci E et al (2012) Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis. Am J Vet Res 73:988–995. https://doi.org/10.2460/ajvr.73.7.988
Cantarella G, Scollo M, Lempereur L et al (2011) Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. Biochem Pharmacol 82:380–388. https://doi.org/10.1016/j.bcp.2011.05.004
Capasso R, Orlando P, Pagano E et al (2014) Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB1 receptors and TRPV1 channels. Br J Pharmacol 171:4026–4037. https://doi.org/10.1111/bph.12759
Cassano T, Calcagnini S, Pace L et al (2017) Cannabinoid receptor 2 signaling in neurodegenerative disorders: from pathogenesis to a promising therapeutic target. Front Neurosci 11:30. https://doi.org/10.3389/fnins.2017.00030
Caterina MJ, Schumacher MA, Tominaga M et al (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389:816–824
Chen DJ, Gao M, Gao FF et al (2017) Brain cannabinoid receptor 2: expression, function and modulation. Acta Pharmacol Sin 38:312–316. https://doi.org/10.1038/aps.2016.149
Chiocchetti R, Giancola F, Mazzoni M et al (2015) Excitatory and inhibitory enteric innervation of horse lower esophageal sphincter. Histochem Cell Biol 143:625–635. https://doi.org/10.1007/s00418-014-1306-y
Cirillo C, Sarnelli G, Esposito G et al (2011) S100B protein in the gut: the evidence for enteroglial-sustained intestinal inflammation. World J Gastroenterol 17:1261
Coutts AA, Irving AJ, Mackie K et al (2002) Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 448:410–422
Cremon C, Stanghellini V, Barbaro MR et al (2017) Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. Aliment Pharmacol Ther 45:909–922. https://doi.org/10.1111/apt.13958
Croci T, Manara L, Aureggi G et al (1998) In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmacol 125:1393–1395
Darmani NA (2010) Mechanisms of broad-spectrum antiemetic efficacy of cannabinoids against chemotherapy-induced acute and delayed vomiting. Pharmaceuticals (Basel) 3:2930–2955. https://doi.org/10.3390/ph3092930
De Petrocellis L, Di Marzo V (2010) Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J Neuroimmune Pharmacol 5:103–121. https://doi.org/10.1007/s11481-009-9177-z
De Petrocellis L, Davis JB, Di Marzo V (2001) Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett 506:253–256
De Filippis D, Negro L, Vaia M et al (2013) New insights in mast cell modulation by palmitoylethanolamide. CNS Neurol Disor Drug Targets 12:78–83
Di Patrizio N (2016) Endocannabinoids in the Gut. Cannabis Cannabinoid Res 1:67–77. https://doi.org/10.1089/can.2016.0001
Di Marzo V, Izzo AA (2006) Endocannabinoid overactivity and intestinal inflammation. Gut 55:1373–1376
Di Marzo V, Piscitelli F (2011) Gut feelings about the endocannabinoid system. Neurogastroenterol Motil 23:391–398. https://doi.org/10.1111/j.1365-2982.2011
Di Marzo V, De Petrocellis L, Fezza F et al (2002) Anandamide receptors. Prostaglandins Leukot Essent FattyAcids 66:377–391
Di Paola R, Impellizzeri D, Torre A et al (2012) Effects of palmitoylethanolamide on intestinal injury and inflammation caused by ischemia-reperfusion in mice. J Leukoc Biol 91:911–920
DiPatrizio NV, Astarita G, Schwartz G et al (2011) Endocannabinoid signal in the gut controls dietary fat intake. Proc Natl Acad Sci USA 108:12904–12908. https://doi.org/10.1073/pnas.1104675108
Dowie MJ, Grimsey NL, Hoffman T et al (2014) Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington’s disease brain. J Chem Neuroanat 59–60:62–71. https://doi.org/10.1016/j.jchemneu.2014.06.004
Duncan M, Davison JS, Sharkey KA (2005a) Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther 22:667–683
Duncan M, Ho W, Shariat N et al (2005b) Distribution of the CB2 receptor in enteric nerves of the rat ileum. Symposium on the Cannabinoids. Burlington, VT, International Cannabinoid Research Society
Duncan M, Mouihate A, Mackie K et al (2008) Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol 295:G78–G87. https://doi.org/10.1152/ajpgi.90285.2008
Eddinger TJ (2009) Unique contractile and structural protein expression in dog ileal inner circular smooth muscle. J Smooth Muscle Res 45:217–230
Escher P, Braissant O, Basu-Modak S et al (2001) Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142:4195–4202
Esposito G, Capoccia E, Turco F et al (2014) Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation. Gut 63:1300–1312. https://doi.org/10.1136/gutjnl-2013-305005
Fabisiak A, Fichna J (2017) Cannabinoids as gastrointestinal anti-inflammatory drugs. Neurogastroenterol Motil. https://doi.org/10.1111/nmo.13038
Facci L, Dal Toso R, Romanello S (1995) Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 92:3376–3380
Farquhar-Smith W, Jaggar S, Rice A (2002) Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB1 and CB2-like receptors. Pain 97:11–21
Freundt-Revilla J, Kegler K, Baumgärtner W et al (2017) Spatial distribution of cannabinoid receptor type 1 (CB1) in normal canine central and peripheral nervous system. PLoS One 12:e0181064. https://doi.org/10.1371/journal.pone.0181064
Freundt-Revilla J, Heinrich F, Zoerner A et al (2018) The endocannabinoid system in canine Steroid-Responsive Meningitis-Arteritis and Intraspinal Spirocercosis. PLoS One 13:e0187197. https://doi.org/10.1371/journal.pone.0187197
Gabrielsson L, Mattsson S, Fowler CJ (2016) Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol 82:932–942. https://doi.org/10.1111/bcp.13020
Giancola F, Fracassi F, Gallucci A et al (2016) Quantification of nitrergic neurons in the myenteric plexus of gastric antrum and ileum of healthy and diabetic dogs. Auton Neurosci 197:25–33. https://doi.org/10.1016/j.autneu.2016.04.004
Giancola F, Rambaldi AM, Bianco F et al (2017) Localization of the 5-hydroxytryptamine 4 receptor in equine enteric neurons and extrinsic sensory fibers. Neurogastroenterol Motil. https://doi.org/10.1111/nmo.13045
Golech SA, McCarron RM, Chen Y et al (2004) Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res 132:87–92
Goyal H, Singla U, Gupta U et al (2017) Role of cannabis in digestive disorders. Eur J Gastroenterol Hepatol 29:135–143
Guida F, Luongo L, Boccella S et al (2017) Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep 7:375. https://doi.org/10.1038/s41598-017-00342-1
Gyires K, Zádori ZS (2016) Role of Cannabinoids in gastrointestinal mucosal defense and inflammation. Curr Neuropharmacol 14:935–951
Hall CN, Reynell C, Gesslein B et al (2014) Capillary pericytes regulate cerebral blood flow in health and disease. Nature 508:55–60. https://doi.org/10.1038/nature13165
He SH (2004) Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol 10:309–318
He SH, Walls AF (1998) Human mast cell chymase induces the accumulation of neutrophils, eosinophils and other inflammatory cells in vivo. Br J Pharmacol 125:1491–1500
He SH, Peng Q, Walls AF (1997) Potent induction of a neutrophil and eosinophil-rich infiltrate in vivo by human mast cell tryptase: selective enhancement of eosinophil recruitment by histamine. J Immunol 159:6216–6225
Ho WS, Barrett DA, Randall MD (2008) ‘Entourage’effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br J Pharmacol 155:837–846
Hu SS, Mackie K (2015) Distribution of the endocannabinoid system in the central nervous system. Handb Exp Pharmacol 231:59–93. https://doi.org/10.1007/978-3-319-20825-1_3
Hu DL, Zhu G, Mori F et al (2007) Staphylococcal enterotoxin induces emesis through increasing serotonin release in intestine and it is downregulated by cannabinoid receptor 1. Cell Microbiol 9:2267–2277. https://doi.org/10.1111/j.1462-5822.2007.00957.x
Huizinga JD, Ambrous K, Der-Silaphet T (1998) Co-operation between neural and myogenic mechanisms in the control of distension-induced peristalsis in the mouse small intestine. J Physiol 506:843–856
Iannotti FA, Di Marzo V, Petrosino S (2016) Endocannabinoids and endocannabinoid-related mediators: targets, metabolism and role in neurological disorders. Prog Lipid Res 62:107–128. https://doi.org/10.1016/j.plipres.2016.02.002
Izzo AA (2004) Cannabinoids and intestinal motility: welcome to CB2 receptors. Br J Pharmacol 142:1201–1202
Izzo AA, Coutts AA (2005) Cannabinoids and the digestive tract. Handb Exp Pharmacol 168:573–598
Izzo AA, Sharkey KA (2010) Cannabinoids and the gut: New developments and emerging concepts. Pharmacol Ther 126:21–38
Izzo AA, Mascolo N, Pinto L et al (1999) The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur J Pharmacol 384:37–42
Jaggar S, Sellaturay S, Rice A (1998) The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyperreflexia associated with inflammation of the rat urinary bladder. Neurosci Lett 253:123–126
Ji H, Wang H, Zhang F et al (2010) PPARγ agonist pioglitazone inhibits microglia inflammation by blocking p38 mitogen-activated protein kinase signaling pathways. Inflamm Res 59:921–929. https://doi.org/10.1007/s00011-010-0203-7
Junginger J, Lemensieck F, Moore PF et al (2014) Canine gut dendritic cells in the steady state and in inflammatory bowel disease. Innate Immun 20:145–160. https://doi.org/10.1177/1753425913485475
Kader KN, Moore LR, Saul JM et al (2001) Isolation and purification of canine adipose microvascular endothelial cells. Microvasc Res 61:220–226. https://doi.org/10.1006/mvre.2001.2296
Karwad MA, Couch DG, Theophilidou, Eb et al (2017a) The role of CB1 in intestinal permeability and inflammation. FASEB J 31:3267–3277. https://doi.org/10.1096/fj.201601346R
Karwad MA, Macpherson T, Wang B et al (2017b) Oleoylethanolamine and palmitoylethanolamine modulate intestinal permeability in vitro via TRPV1 and PPARα. FASEB J 31:469–481. https://doi.org/10.1096/fj.201500132
Ke P, Shao BZ, Xu ZQ et al (2016) Activation of cannabinoid receptor 2 ameliorates dss-induced colitis through inhibiting NLRP3 inflammasome in macrophages. PLoS One 11:e0155076. https://doi.org/10.1371/journal.pone.0155076
Kianian M, Al-Banna NA, Kelly ME et al (2013) Inhibition of endocannabinoid degradation in experimental endotoxemia reduces leukocyte adhesion and improves capillary perfusion in the gut. J Basic Clin Physiol Pharmacol 24:27–33. https://doi.org/10.1515/jbcpp-2012-0065
Kleinschmidt S, Meneses F, Nolte I et al (2007) Characterization of mast cell numbers and subtypes in biopsies from the gastrointestinal tract of dogs with lymphocytic-plasmacytic or eosinophilic gastroenterocolitis. Vet Immunol Immunopathol 120:80–92
Kreitzer FR, Stella N (2009) The therapeutic potential of novel cannabinoid receptors. Pharmacol Ther 122:83–96. https://doi.org/10.1016/j.pharmthera.2009.01.005
Kulkarni-Narla A, Brown DR (2000) Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res 302:73–80
Lanuti M, Talamonti E, Maccarrone M et al (2015) Correction: activation of GPR55 receptors exacerbates oxLDL-induced lipid accumulation and inflammatory responses, while reducing cholesterol efflux from human macrophages. PLoS One 10:e0131850. https://doi.org/10.1371/journal.pone.0131850
Lauckner JE, Jensen JB, Chen HY et al (2008) GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. PNAS 105:2699–2704
Lee Y, Jo J, Chung HY et al (2016) Endocannabinoids in the gastrointestinal tract. Am JPhysiol Gastrointest Liver Physiol 311:G655–G666
Li K, Fichna J, Schicho R et al (2013) A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice. Neuropharma 71:255–263. https://doi.org/10.1016/j.neuropharm.2013.03.029
Ligresti A, De Petrocellis L, Di Marzo V (2016) From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. Physiol Rev 96:1593–1659. https://doi.org/10.1152/physrev.00002.2016
Lin XH, Yuece B, Li YY et al (2011) A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents. Neurogastroenterol Motil 23:862-e342. https://doi.org/10.1111/j.1365-2982.2011.01742.x
Liu YA, Chung YC, Pan ST et al (2013) 3-D imaging, illustration, and quantitation of enteric glial network in transparent human colon mucosa. Neurogastroenterol Motil 25:e324-38. https://doi.org/10.1111/nmo.12115
Lo Verme J, Fu J, Astarita G et al (2005a) The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67:15–19
Lo Verme J, La Rana G, Russo R et al (2005b) The search for the palmitoylethanolamide receptor. Life Sci 77:1685–1698
Lu Y, Anderson HD (2017) Cannabinoid signaling in health and disease. Can J Physiol Pharmacol 95:311–327. https://doi.org/10.1139/cjpp-2016-0346
Maccarrone M, Bab I, Bíró T et al (2015) Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci 36:277–296
Maione S, Costa B, Di Marzo V (2013) Endocannabinoids: a unique opportunity to develop multi-target analgesics pain 154(Suppl 1):S87–S93. https://doi.org/10.1016/j.pain.2013.03.023
Malfitano AM, Basu S, Maresz K et al (2014) What we know and do not know about the cannabinoid receptor 2 (CB2). Semin Immunol 26: 369–379. https://doi.org/10.1016/j.smim.2014.04.002
Marquéz L, Suárez J, Iglesias M et al (2009) Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS One 4:e6893. https://doi.org/10.1371/journal.pone.0006893
Marsicano G, Wotjak CT, Azad SC et al. (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530–534. https://doi.org/10.1038/nature00839
Moreira FA, Grieb M, Lutz B (2009) Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 23:133–144. https://doi.org/10.1016/j.beem.2008.09.003
Moriconi A, Cerbara I, Maccarrone M et al (2010) GPR55: Current knowledge and future perspectives of a purported “Type-3” cannabinoid receptor. Curr Med Chem 17:1411–1429
Muccioli GG, Naslain D, Bäckhed F et al (2010) The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol 6:392. https://doi.org/10.1038/msb.2010.46
Naidenow J, Hrgovic I, Doll M et al (2016) Peroxisome proliferator-activated receptor (PPAR) α and δ activators induce ICAM-1 expression in quiescent non stimulated endothelial cells. J Inflamm 13:27. https://doi.org/10.1186/s12950-016-0135-2
Navarro G, Morales P, Rodríguez-Cueto C et al (2016) Targeting cannabinoid CB2 receptors in the central nervous system. Medicinal chemistry approaches with focus on neurodegenerative disorders. Front Neurosci 10:406. https://doi.org/10.3389/fnins.2016.00406
Nestmann ER (2016) Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potential. Food Sci Nutr 5:292–309. https://doi.org/10.1002/fsn3.392
O’ Sullivan SE (2016) An update on PPAR activation by cannabinoids. Br JPharmacol 173:1899–1910. https://doi.org/10.1111/bph.13497
Ochoa-Cortes F, Turco F, Linan-Rico A et al (2016) Enteric glial cells: a new frontier in neurogastroenterology and clinical target for inflammatory bowel diseases. Inflamm Bowel Dis 22:433–449. https://doi.org/10.1097/MIB.0000000000000667
Pazos MR, Tolón RM, Benito C et al (2008) Cannabinoid CB1 receptors are expressed by parietal cells of the human gastric mucosa. J Histochem Cytochem 56:511–516. https://doi.org/10.1369/jhc.2008.950741
Petrosino S, Di Marzo V (2017) The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol 174:1349–1365. https://doi.org/10.1111/bph.13580
Petrosino S, Schiano Moriello A, Cerrato S et al (2016) The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. Br J Pharmacol 173:1154–1162. https://doi.org/10.1111/bph.13084
Pierezan F, Mansell J, Ambrus A et al (2014) Immunohistochemical expression of ionized calcium binding adapter molecule 1 in cutaneous histiocytic proliferative, neoplastic and inflammatory disorders of dogs and cats. J Comp Pathol 151:347–351. https://doi.org/10.1016/j.jcpa.2014.07.003
Preziosi R, Sarli G, Paltrinieri M (2004) Prognostic value of intratumoral vessel density in cutaneous mast cell tumors of the dog. J Comp Pathol 130:143–151
Ray AP, Griggs L, Darmani NA (2009) Delta 9-tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew. Behav Brain Res 196:30–36. https://doi.org/10.1016/j.bbr.2008.07.028
Re G, Barbero R, Miolo A et al (2007) Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet J 173:21–30
Ross GR, Lichtman A, Dewey WL et al (2012) Evidence for the putative cannabinoid receptor (GPR55)-mediated inhibitory effects on intestinal contractility in mice. Pharmacology 90:55–65. https://doi.org/10.1159/000339076
Ryberg E, Larsson N, Sjögren S et al (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092–1101
Sardinha J, Kelly ME, Zhou J et al (2014) Experimental cannabinoid 2 receptor-mediated immune modulation in sepsis. Mediat Inflamm 2014:978678. https://doi.org/10.1155/2014/978678
Sarnelli G, D’Alessandro A, Iuvone T et al (2016) Palmitoylethanolamide modulates inflammation-associated vascular endothelial growth factor (VEGF) signaling via the Akt/mTOR pathway in a selective peroxisome proliferator-activated receptor alpha (PPAR-α)-dependent manner. PLoS One 11:e0156198. https://doi.org/10.1371/journal.pone.0156198
Sharkey KA (2015) Emerging roles for enteric glia in gastrointestinal disorders. J Clin Invest 125:918–825. https://doi.org/10.1172/JCI76303
Sharkey KA, Wiley JW (2016) Getting into the weed: the role of the endocannabinoid system in the brain-gut axis. Gastroenterology 151:252–266. https://doi.org/10.1053/j.gastro.2016.04.015
Shea-Donohue T, Stiltz J, Zhao A et al (2010) Mast cells. Curr Gastroenterol Rep 12:349–357. https://doi.org/10.1007/s11894-010-0132-1
Sheng WS, Hu S, Min X et al (2005) Synthetic cannabinoid WIN55, 212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 49:211–219
Skaper SD, Facci L, Giusti P (2013) Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. Mol Neurobiol 48:340–352. https://doi.org/10.1007/s12035-013-8487-6
Stella N (2004) Cannabinoid signaling in glial cells. Glia 48:267–277
Storr MA, Sharkey KA (2007) The endocannabinoid system and gut-brain signalling. Curr Opin Pharmacol 7:575–582
Storr M, Sibaev A, Marsicano G et al (2004) Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. Am J Physiol Gastrointest Liver Physiol 286:G110–G117
Svensson M, Chen P, Hammarfjord O (2010) Dendritic cell regulation by cannabinoid-based drugs. Pharmaceuticals 3:2733–2750
Sykaras AG, Demenis C, Case RM et al (2012) Duodenal enteroendocrine I-cells contain mRNA transcripts encoding key endocannabinoid and fatty acid receptors. PLoS One 7:e42373. https://doi.org/10.1371/journal.pone.0042373
Taylor L, Christou I, Kapellos TS et al (2015) Primary macrophage chemotaxis induced by cannabinoid receptor 2 agonists occurs independently of the CB2 receptor. Sci Rep 5:10682. https://doi.org/10.1038/srep10682
Tuduri E, Imbernon M, Bautista R et al (2017) GPR55: a new promising target for metabolism? J Mol Endocrinol 58:R191–R202. https://doi.org/10.1530/JME-16-0253
Van Sickle MD, Oland LD, Ho W et al (2001) Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 121:767–774
Wang J, Zheng J, Kulkarni A et al (2014) Palmitoylethanolamide regulates development of intestinal radiation injury in a mast cell-dependent manner. Dig Dis Sci 59:2693–2703. https://doi.org/10.1007/s10620-014-3212-5
Wille KH1, Schnorr B (2003) The occurrence of hemodynamic effective elements in the intestinal blood vessel system. Anat Histol Embryol 32:94–97
Wouters MM, Vicario M, Santos J (2016) The role of mast cells in functional GI disorders. Gut, 65:155–168. https://doi.org/10.1136/gutjnl-2015-309151
Wright K, Rooney N, Feeney M et al (2005) Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129:437 – 453
Wright KL, Duncan M, Sharkey KA (2008) Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol 153:263–270
Zahradka P, Yurkova N, Litchie B et al (2003) Activation of peroxisome proliferator-activated receptors alpha and gamma1 inhibits human smooth muscle cell proliferation. Mol Cell Biochem 246:105–110
Zelcer E, Daniel EE (1979) Electrical coupling in the circular muscles of dog jejunum. Can J Physiol Pharmacol 57:578–580
Zong Y, Zhou X, Cheng J et al (2017) Cannabinoids regulate the diameter of pericyte-containing retinal capillaries in rats. Cell Physiol Biochem 43:2088–2101. https://doi.org/10.1159/000484193
Zygmunt PM, Petersson J, Andersson DA et al (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452–457
Acknowledgements
We are thankful to Dr. Giovanni Marsicano (INSERM U1215, NeuroCentre Magendie, Team ‘Endocannabinoids and Neuroadaptation’, Bordeaux, France) and to Prof. Giovanna Zoccoli (Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum - University of Bologna) who kindly provided us with brain sample of wild-type and mice with congenital deficiency of CB1. We are thankful to Dr. Catia Barboni (Department of Veterinary Medical Sciences, Alma Mater Studiorum—University of Bologna), who kindly provided us with samples of mouse intestine for the Wb analysis, and with Dr. Marco Luppi (Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum—University of Bologna) who kindly provided with sample of rat intestine for wholemount preparations.
Funding
This research received a grant from Innovet Italia S.r.l. (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Ethical Approval
All applicable international, national and/or institutional guidelines for the care and use of animals were followed.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Galiazzo, G., Giancola, F., Stanzani, A. et al. Localization of cannabinoid receptors CB1, CB2, GPR55, and PPARα in the canine gastrointestinal tract. Histochem Cell Biol 150, 187–205 (2018). https://doi.org/10.1007/s00418-018-1684-7
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00418-018-1684-7